

REFERENCES

- Abbou, C.C. ; Salomon, L. ; Hoznek, A. ; Antiphon, P. ; Cicco, A. ; Saint, F. ; Alame, W. ; Bellot, J. and Chopin, D.K. (2000):** Laparoscopic radical prostatectomy: preliminary results. *Urology* 55:630–634.
- Abbou, C.C.; Hoznek, A.; Salomon, L.; Olsson, L.E.; Lobontiu, A.; Saint, F.; Cicco, A.; Antiphon, P. and Chopin D (2001):** Laparoscopic radical prostatectomy with a remote controlled robot. *J Urol* 165:1964 -1966.
- Allsbrook, W.C. (2001):** Interobserver reproducibility of Gleason grading of prostatic carcinoma. *Urologic pathologists. Hum Pathol* 32:74-80.
- Amin, M.B.; Humphrey, P. A.; Grignon, D. J. and Srigley, J. R. (2004):** Gleason Grading of Prostate Cancer: A Contemporary Approach (1st Edition), *Lippincott Williams & Wilkins PP.* 1-108.
- Anastasiadis, A.G. ; Salomon, L. ; Katz, R. ; Hoznek, A. ; Chopin, D. and Abbou, C.C. (2003):** Radical retropubic versus laparoscopic prostatectomy: a prospective comparison of functional outcome. *Urology* 62:292–297.
- Anastasiadis , A. G.; Lichy , M.P.; Nagele , U. ; Kuczyk , M. A. Merseburger , A. S. ; Hennenlotter , J. ; Corvin , S. ; Sievert , K.; Claussen , C. D.; Stenzl , A. and Schlemmer, H.(2006):** MRI-Guided Biopsy of the Prostate Increases Diagnostic Performance in Men with Elevated or Increasing PSA Levels after Previous Negative TRUS Biopsies *European urology* 50:738–749.
- Arima, K. ; Sugimura, Y. and Hioki, T.(1997):** Stereologically estimated mean nuclear volume of prostatic cancer is a reliable prognostic parameter. *Br J Cancer* 76:234-237.

- Aus, G. ; Abrahamsson, P.A. ; Ahlgren, G. ; Hugosson, J. ; Lundberg, S. ; Schain, M. ; Schelin, S. and Pedersen, K. (2002):** Three-month neoadjuvant hormonal therapy before radical prostatectomy; a 7-year follow-up of a randomized controlled trial. *BJU Int* 90:561–566.
- Avant, O.L. ; Jones, J.A. ; Beck, H. ; Hunt, C. and Straub, M. (2000):** New method to improve treatment outcomes for radical prostatectomy. *Urology* 56:658–662.
- Bader, P. ; Burkhard, F.C. ; Markwalder, R. and Studer, U.E. (2002):** Is a limited lymph node dissection an adequate staging procedure for prostate cancer? *J Urol* 168:514–518.
- Barre, C.; Pocholle, P. and Chauveau, P. (1999):** Improving bladder neck division in radical retropubic prostatectomy by prior dissection of the seminal vesicles and vasa deferentia. *Eur Urol* 36:107–110.
- Bazinet, M. ; Meshref, A.W. and Trudel, C. (1994) :** Prospective evaluation of prostate-specific antigen density and systematic biopsies for early detection of prostatic carcinoma. *Urology* 43:44-51. discussion 51-52.
- Benson, M.C.; Whang, I.S. and Pantuck, A. (1992) :** Prostate specific antigen density: A means of distinguishing benign prostatic hypertrophy and prostate cancer. *J Urol* 147:815-816.
- Beyersdorff, D.; Taupitz, M. and Winkelmann B. (2002):** Patients with a history of elevated prostate-specific antigen levels and negative transrectal US-guided quadrant or sextant biopsy results: value of MR imaging. *Radiology* 224: 701–706.
- Bhayani, S.B.; Pavlovich, C.P.; Hsu, T.S.; Sullivan, W. and Su, L.M. (2003):** Prospective comparison of short-term convalescence: laparoscopic radical prostatectomy versus open radical retropubic prostatectomy. *Urology* 61:612–616.
- Binder, J. and Kramer, W. (2001):** Robotically-assisted laparoscopic radical prostatectomy. *BJU Int* 87:408–410.

- Bishoff, J.T. ; Reyes, A. ; Thompson, I.M. ; Harris, M.J. ; St Clair, S.R. ; Gomella, L. and Butzin, C.A. (1995):** Pelvic lymphadenectomy can be omitted in selected patients with carcinoma of the prostate: development of a system of patient selection. *Urology* 45:270–274.
- Bluestein, D.L.; Bostwick, D.G.; Bergstralh, E.J. and Oesterling, J.E. (1994):** Eliminating the need for bilateral pelvic lymphadenectomy in select patients with prostate cancer. *J Urol* 151:1315–1320.
- Bostwick, D.G.(1994):** Grading prostate cancer. *Am J Clin Pathol* 102[Suppl 1]:S38-S54.
- Bostwick, D.G.(1994b):** Gleason grading of prostatic needle biopsies. Correlation with grade in 316 matched prostatectomies. *Am J Surg Pathol* 18:796-803.
- Bostwick, D.G. and Dundore, P. (1997):**Grading. In: Biopsy Pathology of the Prostate. *Biopsy Pathology Series 20. London: Chapman & Hall Medical*,:141-166.
- Bostwick, D.G.; Grignon, D.J. and Hammond, E.H. (2000):** Prognostic factors in prostate cancer: College of American Pathologists Consensus Statement 1999. *Arch Pathol Lab Med* 124:995-1000.
- Bozeman, C.B.; Carver, B.S. ; Caldito, G.; Venable, D.D. and Eastham JA (2005):** Prostate cancer in patients with an abnormal digital rectal examination and serum prostate-specific antigen less than 4.0 ng/ml. *Urology* 66:803–807.
- Brawer, M.K.; Aramburu, E.A. and Chen, G.L.; (1993):** The inability of prostate specific antigen index to enhance the predictive value of prostate specific antigen in the diagnosis of prostatic carcinoma. *J Urol*; 150:369-373.
- Brawer, M.K.(1999):** Prostate-specific antigen: Current status. *CA Cancer J Clin*; 49:264-281.
- Brossner, C.; Bayer, G. and Madersbacher, S. (2005):** Twelve prostate biopsies detect significant cancer volumes (>0.5 mL). *BJU Int*; 85:705-707

- Bulbul, M.A.; El-Hout, Y.; Haddad, M. M.; Tawil, A.; Houjaij, A. ; Bou Diab,N.N. and Oussama Darwish, O.(2007):** Pathological correlation between needle biopsy and radical prostatectomy specimen in patients with localized prostate cancer. *Canadian Urological Association*, 1(3):264-6.
- Carlson, C.D. ; Calvanese, C. B. And Kahane, H. (1998):** Accuracy of biopsy Gleason scores from a large uropathology laboratory: use of a diagnostic: protocol to minimize observer variability. *Urology* 51:525-529
- Candas, B.; Cusan, L. ; Gomez, J.L. ; Diamond, P. ; Suburu, R.E. ; Levesque, J. ; Brousseau, G. ; Bclanger, A.; and Labrie, F.(2000):** Evaluation of prostate specific antigen and digital rectal examination as screening tests for prostate cancer. *Prostate* 45(1): 19–35.
- Carter, H.B.; Morrell, C.H. and Pearson, J.D.(1992a):** Estimation of prostatic growth using serial prostate-specific antigen measurements in men with and without prostate disease. *Cancer Res*; 52:3323-3328.
- Carter, H.B.; Pearson, J.D. and Metter, E.J. (1992b):** Longitudinal evaluation of prostate-specific antigen levels in men with and without prostate disease. *JAMA*; 267:2215-2220.
- Carter, H.B.; Pearson, J.D. and Waclawiw, Z. (1995):** Prostate-specific antigen variability in men without prostate cancer: Effect of sampling interval on prostate-specific antigen velocity. *Urology* 45:591-596.
- Carter, H. (2000):** A PSA threshold of 4.0 ng/mL for early detection of prostate cancer: The only rational approach for men 50 years old and older. *Urology* 55:796-799.
- Carter, H.B.; Mohamed, E.; Allaf, M.E. and Partin, A.W. (2007):** Diagnosis and Staging of Prostate Cancer. Walsh, P.C; Retik, A.B.; Vaughan, Jr. E.D and Wein, A.J., Campbell's Urology, Vol. 3, (ed) 9th, Philadelphia, W.B. Saunders Co. PP.
- Casciani, E.; Poletti, E. and Bertini L. (2004):** Prostate cancer: evaluation with endorectal MR imaging and three-dimensional proton MR spectroscopic imaging. *Radiol Med* 108:530.

- Catalona, W.J.; Hudson, M.A. and Scardino, P.T. (1994):** Selection of optimal prostate specific antigen cutoffs for early detection of prostate cancer: Receiver operating characteristic curves. *J Urol* 152:2037-2042.
- Catalona, W.J. and Smith, D.S. (1994):** 5-Year tumor recurrence rates after anatomical radical retropubic prostatectomy for prostate cancer. *J Urol*; 152:1837-1842
- Catalona, W.J. ; Smith, D.S. and Wolfert, R.L.(1995):** Evaluation of percentage of free serum prostate-specific antigen to improve specificity of prostate cancer screening. *JAMA*; 274:1214-122
- Catalona, W.J.; Smith, D.S. and Ornstein, D.K. (1997):** Prostate cancer detection in men with serum PSA concentrations of 2.6 to 4.0 ng/mL and benign prostate examination. Enhancement of specificity with free PSA measurements. *JAMA* 277:1452-1455.
- Catalona, W.J. ; Partin, A.W. and Slawin ,K.M. (1998):**
Use of the percentage of free prostate-specific antigen to enhance differentiation of prostate cancer from benign prostatic disease: A prospective multicenter clinical trial. *JAMA*; 279:1542-1547
- Catalona, W.J.; Ramos, C.G.; Carvalhal, G.F. and Yan, Y.(2000b):** Lowering PSA cutoffs to enhance detection of curable prostate cancer. *Urology* 55:791-795.
- Catalona, W.J.; Southwick, P.C. and Slawin, K.M.(2000c):** Comparison of percent free PSA, PSA density, and age-specific PSA cutoffs for prostate cancer detection and staging. *Urology* 56:255-260.
- Cathelineau, X. ; Cahill, D. ; Widmer, H. ; Rozet, F. ; Baumert ,H. and Vallancien, G. (2004):** Transperitoneal or extraperitoneal approach for laparoscopic radical. Prostatectomy: a false debate over a real challenge. *J Urol* 171:714–716
- Chan, D.W.; Kelly, C.A. and Partin, A.W. (1996):** PSA-ACT immunoassay: Problems and solutions. *Clin Chem*; 42:255.
- Chang, J.J.; Shinohara, K.; Bhargava, V. and Presti, J.C. Jr. (1998):** Prospective evaluation of lateral biopsies of the peripheral zone for prostate cancer detection. *J Urol* 160:2111–2114.

- Chen, M.E.; Troncoso, P.; Johnston, D.A.; Tang, K. and Babaian, R.J. (1997):** Optimization of prostate biopsy strategy using computer based analysis. *J Urol* 158:2168–2175.
- Chen, M.E. ; Troncoso, P.; Tang, K. ; Babaian, R.J. and Johnston, D. (1999):** Comparison of prostate biopsy schemes by computer simulation. *Urology* 53:951–960.
- Chon, C.H. ; Lai, F.C. ; McNeal , J.E. and Presti, J.C .Jr. (2002) :** Use of extended systematic sampling in patients with a prior negative prostate needle biopsy. *J Urol* 167:2457–2460.
- Christensson, A. ; Bjork, T. and Nilsson, O. (1993):** Serum prostate specific antigen complexed to alpha 1-antichymotrypsin as an indicator of prostate cancer. *J Urol* 150:100-105.
- Cleary, K.; Melzer, A.; Watson, V.; Kronreif, G. and Stoianovici D.(2006):** Interventional robotic systems: applications and technology state-of-the-art. *Minim Invasive Ther Allied Technol* 15:101–13.
- Cookson, M.S.; Fleshner, N.E. and Soloway, S.M. (1998):** Correlation between Gleason score of needle biopsy and radical prostatectomy specimens: Accuracy and clinical implications. *J Urol* 157:559-562.
- Cooner, W.H.; Mosley, B.R. and Rutherford, Jr. C.L. (1990):** Prostate cancer detection in a clinical urological practice by ultrasonography, digital rectal examination and prostate specific antigen. *J Urol* 143:1146-1152.discussion 1152-1154.
- Cornud, F. ; Belin, X. ; Piron, D.; Chretien, Y. ; Flam, T. ; Casanova, J.M. ; Helenon, O. ; Mejean, A. ; Thiounn, N. and Moreau, J.F. (1997):** Color Doppler-guided prostate biopsies in 591 patients with an elevated serum PSA level: impact on Gleason score for nonpalpable lesions. *Urology* 49:709–715.
- Crawford, E.D.; Leewansangtong, S. and Goktas, S. (1999):** Efficiency of prostate-specific antigen and digital rectal examination in screening, using 4.0 ng/ml and age-specific reference range as a cutoff for abnormal values. *Prostate* ; 38:296-302.

- Crawford, E.D. ; Batuello, J.T. ; Snow, P. ; Gamito, E.J. ; McLeod, D.G. ; Partin, A.W. ; Stone, N. ; Montie, J. ; Stock, R. ; Lynch, J. and Brandt, J. (2000):** The use of artificial intelligence technology to predict lymph node spread in men with clinically localized prostate carcinoma. *Cancer* 88:2105–2109.
- Cupp, M.R.; Bostwick D.G.; Myers, R.P. and Oesterling, J.E. (1995):** The volume of prostate cancer in the biopsy specimen cannot reliably predict the quantity of cancer in the radical prostatectomy specimen on an individual basis. *J Urol* 153:1543–1548.
- Curto, F.; Benijts, J.; Pansadoro, A.; Barmoshe, S. ; Hoepffner, J.L.; Mugnier, C. ; Piechaud, T. and Gaston, R. (2006):** Nerve sparing laparoscopic radical prostatectomy: our technique. *Eur Urol* 49:344–352.
- D’Amico, A.V.; Tempany, C.M. and Cormack, R.(2000):** Transperineal magnetic resonance image guided prostate biopsy. *J Urol* 164:385–387.
- Demura, T.; Hioka, T. and Furuno, T. (2005):** Differences in tumor core distribution between palpable and nonpalpable prostate tumors in patients diagnosed using extensive transperineal ultrasound-guided template prostate biopsy. *Cancer* 103:1826–32.
- Derweesh, I.H.; Rabets, J.C. and Patel, A. (2004):** Prostate biopsy: Evolving indications and techniques. *Contemp Urol* 16:28-44.
- Deshmukh, N. and Foster, C.S. (1998):** Grading prostate cancer. In: Foster CS, Bostwick DG, and eds. *Pathology of the Prostate*. Philadelphia: WB Saunders: 191-227.
- Desmond, P.M. ; Clark, J. and Thomson, I.M. (1993):** Morbidity with contemporary prostate biopsy. *J Urol* 150:1425-1426.
- Diamond, D.A. ; Berry, S.J. and Jewett, H.J.(1982):** A new method to assess metastatic potential of human prostate cancer: Relative nuclear roundness. *J Urol* 128:729.

- Divrik, R.T.; Eroglu, A.; Sahin, A.; Zorlu, F. and Ozen, H. (2007):** Increasing the number of biopsies increases the concordance of Gleason Score needle biopsies and prostatectomy specimens. *Urology Oncology: Seminars and Original Investigation*, 25: 376-382.
- Djavan, B. ; Zlotta, A.R. and Remzi, M. (1999b):** Total and transition zone prostate volume and age: How do they affect the utility of PSA-based diagnostic parameters for early prostate cancer detection?. *Urology* 54:846-852.
- Djavan, B. ; Zlotta, A. and Remzi, M. (2000):** Optimal predictors of prostate cancer on repeat prostate biopsy: A prospective study of 1,051 men. *J Urol* ; 163:1144-1148.discussion 1148-1149.
- Djavan, B.; Ravery, V.; Zlotta, A.; Dobronski, P.; Dobrovits, M.; Fakhari, M.; Seitz, C. ; Susani, M.; Borkowski, A.; Boccon-Gibod, L.; Schulman, C.C. and Marberger, M. (2001):** Prospective evaluation of prostate cancer detected on biopsies 1, 2, 3 and 4: when should we stop? *J Urol* 166:1679–1683.
- Djavan, B. ; Remzi, M. and Marberger, M.(2003):** When to biopsy and when to stop biopsying. *Urol Clin N Am* 30:253-262.
- Dubernard, P. ; Benchetrit, S. ; Chaffange, P. ; Hamza, T. and Van Box Som, P. (2003):** Retrograde extraperitoneal laparoscopic prostatectomy (R.E.I.P) Simplified technique (based on a series of 143 cases (in French). *Prog Urol* 13:163–17.
- Elabbady, A.A.and Khedr, M.M. (2006):** Extended 12-core prostate biopsy increases both the detection of prostate cancer and the accuracy of Gleason score. *Eur Urol* 49:49–53.
- Elgamal, A.A. ; Van Poppel, H.P. ; Van de Voorde, W.M. ; Van Dorpe, J.A. ; Oyen, R.H. and Baert, L.V. (2007):** Impalpable invisible stage T1c prostate cancer: characteristics and clinical relevance in 100 radical prostatectomy specimens—a different view. *J Urol* 157:244–250.
- Emiliozzi, P.; Longhi, S.; Scarpone, P.; Pansadoro, A.; DePaula, F. and Pansadoro V.(2001):**The value of a single biopsy with 12

transperineal cores for detecting prostate cancer in patients with elevated prostate specific antigen. *J Urol* 166: 845–850.

Emiliozzi, P.; Maymone, S.; Paterno, A.; Scarpone, P.; Amini, M. Proietti, G.; Cordahi, M. and Pansadoro, V. (2004): Increased accuracy of biopsy Gleason score obtained by extended needle biopsy. *J Urol* 172:2224–2226.

Engelhard, K.; Hollenbach, H.P.; Kiefer, B.; Winkel, A.; Goeb, K. and Engehausen D.(2006): Prostate biopsy in the supine position in a standard 1.5-T scanner under real time MR-imaging control using a MR-compatible endorectal biopsy device. *Eur Radiol* 16:1237–1243.

Epstein, J.I.(2000): Gleason score 2 to 4 adenocarcinoma of the prostate on needle biopsy: A diagnosis that should not be made. *Am J Surg Pathol* 24:477-478.

Epstein, J.I. and Potter, S.R. (2001): The pathological interpretation and significance of prostate needle biopsy findings: implications and current controversies. *J Urol* 166:402–410.

Erdogru, T. ; Teber, D. ; Frede, T. ; Marrero, R. ; Hammady, A. ; Seemann, O. and Rassweiler, J. (2004): Comparison of transperitoneal and extraperitoneal laparoscopic radical prostatectomy using match-pair analysis. *Eur Urol* 46:312–319.

Eskew, L.A.; Bare, R.L. and McCullough, D.L. (1997): Systematic 5 region prostate biopsy is superior to sextant method for diagnosing carcinoma of the prostate. *J Urol* 157:199–202; discussion 202–203.

Farnham, S.B. ; Webster, T.M. ; Herrell, S.D. and Smith, J.A. Jr. (2006): Intraoperative blood loss and transfusion requirements for robotic-assisted radical prostatectomy versus radical retropubic prostatectomy. *Urology* 67:360–363.

Ficarra, V.;Novella, G. and Novara, G. (2005): The potential impact of prostate volume in the planning of optimal number of cores in the systematic transperineal prostate biopsy. *Eur Urol* 48:932–937.

Fichtinger, G.; Krieger, A.; Susil, R.C.; Tanacs ,A.; Whitcomb, L.L. and Atalar E. T.(2002): Transrectal prostate biopsy inside closed

MRI scanner with remote actuation, under real-time image guidance. *Lecture Notes in Comput Sci* 2488:91–98.

Fitzsimons, N.J. ; Banez, L. ; Sun, L. and Moul, J. W.(2008): Prostate Biopsy Indications, Techniques, and Complications, J. Stephen Jones, Humana Press PP. 287-312.

Flemming, I.D.; Cooper, I.S. and Hemson, D.E.(1997):ed. American Joint Committee on Cancer Staging Manual, 5th ed.. Philadelphia: JB Lippincott 219-222.

Fleshner, N.E.; Cookson, M.S. and Soloway, S.M. (1998): Repeat transrectal ultrasound-guided prostate biopsy: A strategy to improve the reliability of needle biopsy grading in patients with well-differentiated prostate cancer. *Urology* 52:659-662.

Fukagai, T. ; Namiki, T. And Namiki, H. (2001): Discrepancies between Gleason scores of needle biopsy and radical prostatectomy specimens.*Pathol Int* 51:364 –70.

Gann, P.H. ; Hennekens, C.H. and Stampfer ,M.J.(1995):A prospective evaluation of plasma prostate-specific antigen for detection of prostatic cancer. *JAMA* 273:289-294.

Gardner, T.A.; Lemer, M.L.; Schlegel, P.N.; Waldbaum, R.S.; Vaughan, E. DJr. and Steckel, J. (1998): Microfocal prostate cancer: biopsy cancer volume does not predict actual tumour volume. *Br J Urol* 81:839–843.

Garzotto, M. ; Park, Y.; Mongoue-Tchokote, S. ; Bledsoe, J. ; Peters, L. ; Blank, B.H.; Austin, D.; eer, T.M. and Mori, M. (2005): Recursive partitioning for risk stratification in men undergoing repeat prostate biopsies. *Cancer* 104:1911–1917

Gettman, M.T. ; Hoznek, A. ; Salomon, L. ; Katz, R. ; Borkowski, T. ; Antiphon, P. ; Lobontiu, A. and Abbou, C.C. (2003): Laparoscopic radical prostatectomy: description of the extraperitoneal approach using the da Vinci robotic system. *J Urol* 170:416–419

- Gleason, D.F.(1966):** Classification of prostatic carcinoma. *Cancer Chemother Rep* 50:125-128.
- Gleason, D.F. ; Mellinger, G.T. and the Veterans Administration Cooperative Urological Research Group (1974):** Prediction of prognosis for prostatic adenocarcinoma by combined histological grading and clinical staging. *J Urol* 111:58-64.
- Gleason, D.F. and the Veterans Administration Cooperative Urological Research Group (1977):** Histologic grading and clinical staging of prostatic carcinoma. In: Tannenbaum M, ed. *Urologic Pathology: The Prostate. Philadelphia: Lea & Febiger: 171-197.*
- Gleason, D.F.(1990):** Histologic grading of prostatic carcinoma. In: Bostwick DG, ed. *Pathology of the Prostate. New York: Churchill Livingstone: 91-92.*
- Gleason, D.F.(1992b):** Histologic grading of prostatic carcinoma. In: Bostwick DG, ed. *Pathology of the Prostate. New York: Churchill Livingstone:83-93.*
- Gleason, D.F.(1992):** Histologic grading of prostate cancer: A perspective. *Hum Pathol* 23:273-279.
- Gleave, M.E. ; Goldenbergh, L. ; Chin, J.L. ; Warnes, J. ; Saad, F. ; Klotz, L. ; Jewett, M. ; Kassabian, V. ; Chetner, M. and Dupont, C. (2003):** Randomized comparative study of 3 vs 8 months of neoadjuvant hormonal therapy prior to radical prostatectomy: 3 year PSA recurrence rates. *J Urol* 169 (Suppl):179 Abstr 690.
- Gonzalzo, M.L.; Bastian, P.J.; Mangold, L.A.; Trock, B.J.; Epstein, J.I.; Walsh, P.C. and Partin, A.W. (2006):** Relationship between primary Gleason pattern on needle biopsy and clinicopathologic outcomes among men with Gleason Score 7 adenocarcinoma of the prostate. *Urology*, 67: 115-119.
- Goossen, T.E. ; de la Rosette, J.J. ; Hulsbergen-van de Kaa,**

- C.A.; van Leenders, G.J. and Wijkstra, H. (2003):** The value of dynamic contrast enhanced power Doppler ultrasound imaging in the localization of prostate. *Cancer. Eur Urol* 43:124–131.
- Gore, J.L. ; Shariat, S.F. ; Miles, B.J.; Kadmon, D. ; Jiang, N. ; Wheeler, T.M. and Slawin, K.M. (2001) :** Optimal combination of systematic sextant and laterally directed biopsies for the detection of prostate cancer. *J Urol* 165:1554–1559.
- Gospodarowicz, M.K. ; Henson, D.E. and Hutter, R.V.P. (2001):**eds. UICC Prognostic Factors in Cancer. 2nd ed. New York: Wiley-Liss,.
- Greene, F.L. ; Page, D.L. and Flemming, I.D. (2002):**eds. AJCC Cancer Staging Manual, 6th ed. New York: Springer-Verlag New York,.
- Grossklauss, D.J. ; Coffey, C.S. ; Shappell, S.B. ; Jack, G.S. ; Sam, S. ; Chang, S.S. and Cooksob, M.S., (2002) :** Percent of cancer in the biopsy set predicts pathological findings after prostatectomy *American urological association*, vol. 167,2032-2036.
- Grossfeld, G.D. ; Chang, J.J. ; Broering, J. M. ; Li, Y.P. ;Lubeck, D.P. ; Flanders, S.C. and Carroll, P.R. (2001) :** Understaging and undergrading in a contemporary series of patients undergoing radical prostatectomy : results from the cancer of the prostate strategic urologic research endeavor database *The journal of urology* , vol,165,851-85.
- Guillonneau, B. and Vallancien, G. (2000):** Laparoscopic radical prostatectomy: the Montsouris technique. *J Urol* 163:1643–1649.
- Haese, A.; Graefen, M. and Noldus, J.(1997):** Prostatic volume and ratio of free-to-total prostate specific antigen in patients with prostatic cancer or benign prostatic hyperplasia. *J Urol* 158:2188-2192.
- Hambrock, T; Somford, D.M.; Hoeks, C.; Bouwense, S. A.W. ; Huisman, H.; Yakar, D.; van Oort, I. M.; Witjes, J. A ;J Fütterer, J. and Barentsz J. O.(2010):**Magnetic Resonance Imaging Guided Prostate Biopsy in Men With Repeat Negative

Biopsies and Increased Prostate Specific Antigen *The Journal Urology*, 183:520-528.

Hammond, M.E. ; Fitzgibbons, P.L. ; Compton, C.C. and College of American Pathologists Conference XXXV(2000): Solid tumor prognostic factors—which, how, and so what? *Arch Pathol Lab Med.* 7:958-965.

Han, M. ; Partin, A.W. ; Pound, C.R. ; Epstein, J.I. and Walsh, P.C. (2001): Long-term biochemical disease-free and cancer-specific survival following anatomic radical retropubic prostatectomy. The 15-year Johns Hopkins experience. *Urol Clin North Am* 28:555–565.

Haker, S.J.; Mulkern, R.V. and Roebuck, J.R.(2005): Magnetic resonance- guided prostate interventions. *Top Magn Reson Imaging* 16:355–368.

Han, M.; Walsh P. and Partin, A. (2000): Ability of the 1992 and 1997 American Joint Committee on cancer staging systems for prostate cancer to predict progression-free survival after radical prostatectomy for stage T2 disease. *J Urol* 164:89.

Hankey, B.F. ; Feuer, E.J.; Clegg, L.X. ; Hayes ,R.B. ; Legler, J.M.; Prorok, P.C. ; Ries, L.A. ; Merrill, R.M. and Kaplan, R.S. (1999): Cancer surveillance series: interpreting trends in prostate cancer- part I: Evidence of the effects of screening in recent prostate cancer incidence, mortality, and survival rates. *J Natl Cancer Inst* 91:1017–1024.

Hara, I. ; Kawabata, G. ; Miyake, H. ; Nakamura, I. ; Hara, S. ; Okada, H. and Kamidono, S. (2003): Comparison of quality of life following laparoscopic and open prostatectomy for prostate cancer. *J Urol* 169:2045–2048.

Hata, N.; Jinzaki, M. and Kacher, D.(2001): MR imaging-guided prostate biopsy with surgical navigation software: device validation and feasibility. *Radiology* 220:263–268.

Hayek, O.R. ; Noble, C.B. and de la Taille, A. (1999): The necessity of a second prostate biopsy cannot be predicted by PSA or PSA

derivatives (density or free:total ratio) in men with prior negative prostatic biopsies. *Curr Opin Urol* 9:371-375.

Heidenreich, A. ; Varga, Z. and Von Knobloch, R. (2002): Extended pelvic lymphadenectomy in patients undergoing radical prostatectomy: high incidence of lymph node metastasis. *J Urol* 167:1681–1686.

Heidenreich, A. ; Ohlmann, CH. ; Zg ,E. ; Btaun, M. and Engelmann, U.H. (2005): Extended retropubic radical prostatectomy in clinical stage T3 prostate cancer: significant reduction of positive surgical margins in a case control study. *Eur Urol Suppl* 4:8.

Heidenreich, A. (2007): Guidelines and Counselling for Treatment Options in the Management. Ramon, J. and Denis, L. J., Prostate Cancer, Recent Results in Cancer Research, *Springer-Verlag Berlin Heidelberg* PP. 131-162.

Hodge, K.K. ; McNeal ,J.E. ; Terris, M.K. and Stamey. T.A. (1989): Random systematic versus directed ultrasound guided transrectal core biopsies of the prostate. *J Urol* 142:71–4; discussion 74–75.

Holmberg, L ; , Bill-Axelson, A. ; Helgesen, F. ; Salo, J.O. ; Folmerz, P. ; Haggman, M. ; Andersson, S.O. ; Spangberg, A. ; Busch, C. ; Nordling, S. ; Palmgren, J. ; Adami, H.O. ; Johansson, J.E. and Norlen, B.J. for the Scandinavia Prostatic Cancer Group Study Number 4 (2002) : A randomized trial comparing radical prostatectomy with watchful waiting in early prostate cancer. *N Engl J Med* 347:781–78.

Horninger, W. ; Cheli, C.D. and Babaian, R.J.(2002): Complexed prostate-specific antigen for early detection of prostate cancer in men with serum prostate-specific antigen levels of 2 to 4 nanograms per milliliter. *Urology* 60(4 Suppl 1):31-35.

Hoznek, A. ; Antiphon, P. ; Borkowski, T. ; Gettman, M.T. ; Katz, R. ; Salomon, L. ; Zaki, S. ; de la Taille, A. and Abbou, C.C. (2003): Assessment of surgical technique and perioperative

morbidity associated with extraperitoneal versus transperitoneal laparoscopic radical prostatectomy. *Urology* 61:617–622.

Hoznek, A.; Menard, Y.; Salomon, L. and Abbou, C.C. (2003): Update on laparoscopic and robotic radical prostatectomy. *Curr Opin Urol* 15:173 -180

Hsieh, T.F. ; Chang, C. H. ; Chen, W.C. ; Chou, C.L. ; Chen, C.C. and Wu, H.C.(2005): Correlation of Gleason Scores Between Needle-Core Biopsy and Radical Prostatectomy Specimens in Patients with Prostate Cancer. *J Chin Med Assoc* 68(4):167–171.

Huland, H. (1997): Treatment of localized disease: treatment of clinically localized prostate cancer (T1/T2). In: Murphy G, Denis L, Chatelain C, Griffiths K, Khoury S, Cockett AT (eds) Proceedings of the First International Consultation on Prostate Cancer. *Scientific Communication International, Jersey*, pp 227–257.

Iczkowski, K.A. and Bostwick, D.G. (1999): Prostate biopsy interpretation current concepts. *Urol Clin North Am* 26:435-452.

Imamoto, T.; Suzuki, H.; Utsumi, T.; Takano, M.; Suyama, T.; Kawamura, K.; Kamiya, N.; Naya, Y.; Ueda, T. and Ichikawa, T.(2009): External Validation of a Nomogram Predicting the Probability of Prostate Cancer Gleason Sum Upgrading Between Biopsy and Radical Prostatectomy Pathology Among Japanese Patients.*Elsevier*:1-7.

Iyer, R.; Hanlon, A. and Pinover, W. (1999): Outcome evaluation of the 1997 American Joint Committee on cancer staging system for prostate carcinoma treated by radiation therapy. *Cancer* 85:1816.

Jehonathan, H.; Pinthus ; Dalibor Pacik, and Jacob Ramon, (2007): Diagnosis of Prostate Cancer. Ramon, J. and Denis, L. J., Prostate Cancer, Recent Results in Cancer Research, *Springer-Verlag Berlin Heidelberg PP.* 83-100.

- Jewett, H.J. ; Bridge, R.W. and Gray, G.F. Jr.(1968):** The palpable nodule of prostatic cancer. *JAMA* 203:115-118.
- Jorgensen, T. ; Yogesan, K. and Tveter, K.J. (1996):** Nuclear texture analysis: A new prognostic tool in metastatic prostate cancer. *Cytometry* 24:277-283.
- Kadmon, D. ; Weinberg, A.D. and Williams, R.H. (1996):** Pitfalls in interpreting prostate specific antigen velocity. *J Urol* 155:1655-1657.
- Kalish, J. ; Cooner, W.H. and Graham, Jr. S.D.(1994):** Serum PSA adjusted for volume of transition zone (PSAT) is more accurate than PSA adjusted for total gland volume (PSAD) in detecting adenocarcinoma of the prostate. *Urology* 43:601-606.
- Karakiewicz ,P.I. ; Bazinet, M. ; Aprikian, A.G. ; Trudel, C. Aronson, S. ; Nachabe, M. ; Peloquin, F. ; Dessureault, J.; Goyal, M.S. ; Begin, L.R. and Elhilali, M.M. (1997):** Outcome of sextant biopsy according to gland volume. *Urology* 49:55–59
- Karakiewicz P.I. ; Perrotte, P. ; McCormack, M. ; Peloquin,F. ; Perreault, J.P. ; Arjane, P. ; Widmer, H. and Saad, F. (2005):** Early detection of prostate cancer with ultrasoundguided systematic needle biopsy. *Can J Urol* 12 Suppl 2:5–8.
- Keetch, D.W. ; Catalona, W.J. and Smith, D.S.(1994)):** Serial prostatic biopsies in men with persistently elevated serum prostate specific antigen values. *J Urol* 151:1571-1574.
- Kimura, G.; Nishimura, T.; Kimata, R.; Saito, Y. and Yoshida,K.(2005):** Random systematic sextant biopsy versus power Doppler ultrasound-guided target biopsy in the diagnosis of prostate cancer: positive rate and clinicopathological features. *J Nippon Med Sch* 72:262–9.
- King, C.R. (2000):** Patterns of prostate cancer biopsy grading: Trends and clinical implications. *Int J Cancer* 90:305–11.

- Klotz, L. (2002):** Active surveillance versus radical treatment for favorable risk localized prostate cancer. *Curr. Treat. Options Oncol.* 7: 355-362.
- Korman, H.J. ; Leu, P.B. ; Huang, R.R. and Goldstein, N.S. (2002):** A centralized comparison of radical perineal and retropubic prostatectomy specimens: is there a difference according to the surgical approach? *J Urol* 168:991–994
- Kossoff, G. (2000) :** Basic physics and imaging characteristics of ultrasound. *World J Surg* 24:134-142.
- Krieger, A.; Susil; R.C. and Menard C.(2005):** Design of a novel MRI compatible manipulator for image guided prostate interventions. *IEEE Trans Biomed Eng* 52:306–313.
- Kuriyama, M.(1998):** Standardization of PSA assays. *Nippon Rinsho* 56:1998-2002.
- Lance, R.S. ; Freidrichs, P.A. ; Kane, C. ; Powell, C.R. ; Pulos, E. ; Moul, J.W. ; McLeod, D.G. ; Cornum, R.L. and Thrasher, B.J. (2001):** A comparison of radical retropubic with perineal prostatectomy for localized prostate cancer within the Uniformed Services Urology Research Group. *BJU Int* 87:61–65.
- Larré,S.; Salomon, L. and Abbou,C.C.(2007):** Choices for Surgery. Guidelines and Counselling for Treatment Options in the Management. Ramon, J. and Denis, L. J., Prostate Cancer, Recent Results in Cancer Research, *Springer-Verlag Berlin Heidelberg PP.* 163-178.
- Leinonen, J. ; Lovgren, T. ; Vornanen, T. and Stenman, U.H.(1993):** Double-label time-resolved immunofluorometric assay of prostate specific antigen and of its complex with alpha 1-antichymotrypsin *Clin Chem* 39:2098-2103.
- Lepor, H. ; Wang, B. and Shapiro, E.(1994):** Relationship between prostatic epithelial volume and serum prostate specific antigen levels. *Urology* 44:199-205.
- Levine, M.A. ; Ittman, M. ; Melamed, J. and Lepor ,H. (1998):** Two consecutive sets of transrectal ultrasound guided sextant biopsies of the prostate for the detection of prostate cancer. *J Urol* 159:471–5; discussion 475–476.

- Lilja, H.(1993a):** Significance of different molecular forms of serum PSA. The free,noncomplexed form of PSA versus that complexed to alpha 1-antichymotrypsin. *Urol Clin North Am* ; 20:681-686.
- Lilja, H.(1997):** Prostate-specific antigen: Molecular forms and the human kallikrein gene family. *Br J Urol* 79(Suppl 1):44-48.
- Lilja,H.; Christensson, A. and Dahlen, U. (1991):** Prostate-specific antigen in serum occurs predominantly in complex with alpha 1-antichymotrypsin. *Clin Chem* 37:1618-1625.
- Matthew, B.; Gretzer and Parten,W.A.(2007):** Prostate Cancer Tumor Markers. Walsh, P.C; Retik, A.B.; Vaughan, Jr. E.D and Wein, A.J., Campbell's Urology, Vol. 3, (ed) 9th, Philadelphia, W.B. Saunders Co. PP. 1337-1378.
- Makarov, D.V. ; Sanderson, H. ; Partin, A.W. and Epstein, J.I. (2002):** Gleason score 7 prostate cancer on needle biopsy : is the prognostic difference in Gleason scores 4-3 and 3-4 independent of the number of involved cores . *The journal of urology* 167: 2440–2442.
- Makhlouf, A.A. ; Krupski, T.L. and Kunkle, D. (2004):** The effect of sampling more cores on the predictive accuracy of pathological grade and tumour distribution in the prostate biopsy. *BJU Int* 93:271– 4.
- Mazhar, D. and Waxman, J. (2002):** Prostate cancer. *Postgrad Med J* 78:590-595.
- McCormack, R.T. ; Rittenhouse, H.G. and Finlay, J.A. (1995) :** Molecular forms of prostate-specific antigen and the human kallikrein gene family: A new era. *Urology* 45:729-744.
- McLaughlin, J.R. ; Dryer, D. and Mao, Y. (2002):** National Cancer Institute of Canada: Canadian Cancer Statistics 2002, *Toronto, Canada*:55-56.
- McNeal, J.E. ; Reese, J.H. and Redwine, E.A.(1986):** Cribriform adenocarcinoma of the prostate. *Cancer* 58:1714-1719.

- McNeal, J.E. and Yemoto, C.E.M.(1996):** Spread of adenocarcinoma within prostatic ducts and acini. *Am J Surg Pathol* 20:802-817.
- Mellinger, G.T. ; Gleason, D. and Bailar, J. III. (1967):** The histology and prognosis of prostatic cancer. *J Urol* 97:331-337.
- Menon, M. ; Shrivastava, A. and Tewari, A. (2005):** Laparoscopic radical prostatectomy: conventional and robotic. *Urology* 66:101–104
- Meng, M.V. ; Franks, J.H. ; Presti, J. C.Jr. and Shinohara, K. (2003):** The utility of apical anterior horn biopsies in prostate cancer detection. *Urol Oncol* 21:361–365.
- Menon, M.; Tewari, A. and Peabody, J. (2003) :** Vattikuti Institute prostatectomy: technique. *J Urol* 169:2289–2292.
- Mikolajczyk, S.D. ; Grauer, L.S. and Millar, L.S. (1997) :** A precursor form of PSA (pPSA) is a component of the free PSA in prostate cancer serum. *Urology* 50:710-714.
- Mikolajczyk, S.D. ; Millar, L.S. and Wang, T.J.,(2000):** A precursor form of prostate-specific antigen is more highly elevated in prostate cancer compared with benign transition zone prostate tissue. *Cancer Res* 60:756-759.
- Mikolajczyk, S.D. ; Marker, K.M., and Millar, L.S. (2001) :** A truncated precursor form of prostate-specific antigen is a more specific serum marker of prostate cancer. *Cancer Res* 61:6958-6963.
- Mikolajczyk, S.D.; Marks, L.S.; Partin, A.W. and Rittenhouse HG (2002):** Free prostate-specific antigen in serum is becoming more complex. *Urology* 59:797-802.
- Mokulis, J. and Thompson, I. (1997):** Radical prostatectomy: is the perineal approach more difficult to learn? *J Urol* 157:230–232.
- Mostofi, F.K. ; Sesterhenn, I. and Sobin, L.H.(1980):** Histological typing of prostate tumours. International histological classification of tumours, no. 22. Geneva: World Health Organization.

- Morgan, T.O. ; Jacobsen, S.J. and McCarthy, W.F.(1996):** Age-specific reference ranges for prostate-specific antigen in black men. *N Engl J Med* 335:304-310.
- Myrtle, J. and Ivor, L. (1989):** Measurement of PSA in serum by two immunometric methods (Hybritech Tandem-R/Tandem-E PSA). In: Catalona WJ, ed. *Clinical Aspects of Prostate Cancer*, New York: Elsevier: 161-171.
- Naya, Y.; Ochiai ,A. ; Troncoso, P. And Babaian, R.J. (2004):** A comparison of extended biopsy and sextant biopsy schemes for predicting the pathological stage of prostate cancer. *J Urol* 171:2203–2208.
- Newcomer, L.M. ; Stanford, J.L. ; Blumenstein, B.A. and Brawer, M.K. (1997):** Temporal trends in rates of prostate cancer: declining incidence of advanced stage disease, 1974 to 1994. *J Urol* 158:1427–1430 PP. 241-252.
- Nielsen, K. ; Berild, G.H. and Bruun, E.(1992):** The prognostic value of histological grading and mean nuclear volume in human prostatic cancer. *Prostate* 21:53-61.
- Noguchi, M.; Stamey, T.A.; Neal, J.E. and Yemoto, C.E. (2000):** An analysis of 148 consecutive transition zone cancers: clinical and histological characteristics. *J Urol* 163:1751–1755.
- Noguchi,M. ;Stamey, T.A. ; Mcneal,J.E. and Yemoto, C.M.(2001):** Relationship between systematic biopsies and histological features os 222 radical prostatectomy specimens : lack of predictionof tumor significance for men with nonpalpable prostate cancer. *The journal of urology*,Vol. 166, 104–110.
- Novella, G.; Ficarra, V. and Galfano, A. (2003):** Pain assessment after original transperineal prostate biopsy using a coaxial needle. *Urology* 62:689–692.
- Oesterling, J.E. ; Jacobsen, S.J. and Chute, C.G. (1993b) :** Serum prostate-specific antigen in a community-based population of healthy men. Establishment of age-specific reference ranges. *JAMA* 270:860-864.
- Onik, G.and Barzell, W.(2008):** Transperineal 3D mapping biopsy of the prostate: An essential tool in selecting patients for focal prostate

cancer therapy *Urologic Oncology: Seminars and Original Investigations* 26 506–510.

Onur, R.; Littrup, P.J. ; Pontes, J.E. and Bianco, Jr. F.J.(2004):

Contemporary impact of transrectal ultrasound lesions for prostate cancer detection. *J Urol* 172:512-514.

Park, H.K. ; Choe, G. ; Byun, S.S. ; Lee, H.W. ; Lee, S.E. and Lee, E. (2006): Evaluation of concordance of Gleason score between prostatectomy and biopsies that show more than two different Gleason scores in positive cores.*Urology* 67: 110-114.

Parra, R.O. ; Boullier, J.A. ; Rauscher, J.A. and Cummings, J.M. (1994):The value of laparoscopic lymphadenectomy in conjunction with radical perineal or retropubic prostatectomy. *J Urol* 151:1599–1602.

Partin, A.W. ; Kattan, M.W. ; Subong, E.N. ; Walsh, P.C. ; Wojno, K.J. ; Oesterling, J.E. ; Scardino, P.T. and Pearson, J.D. (1997):Combination of prostate-specific antigen, clinical stage, and Gleason score to predict pathological stage of localized prostate cancer. A multi-institutional update. *JAMA* 277:1445–1451.

Partin ,A.W. ; Brawer, M.K. and Subong, E.N.(1998): Prospective evaluation of percent free-PSA and complexed-PSA for early detection of prostate cancer.*Prostate Cancer Prostatic Dis* 1:197-203.

Partin, A.W. ; Mangold, L.A. ; Lamm, D.M. ; Walsh, P.C. ; Epstein, J.I., and Pearson, J.D. (2001): Contemporary update of prostate cancer staging nomograms (Partin Tables) for the new millennium. *Urology* 58:843–848.

Pasticier, G. ; Rietbergen, J.B. ; Guillonneau, B. ; Fromont, G. ; Menon, M. and Vallancien, G. (2001): Robotically assisted laparoscopic radical prostatectomy: feasibility study in men. *Eur Urol* 40:70–74.

Perez-Guillermo, M. ; Acosta-Ortega, J. and Garcia-Solano, J.(2005): The continuing role of fine-needle aspiration of the prostate gland into the 21st century: A tribute to Torsten Lowhagen. *Diagn Cytopathol* 32:315-320.

- Peter, J. ; Unverzagt, C. and Krogh, T.N.(2001):** Identification of precursor forms of free prostate-specific antigen in serum of prostate cancer patients by immunosorption and mass spectrometry. *Cancer Res* 61:957-962.
- Pinkstaff, D.M. ; Igel, T.C. and Petrou, S.P.(2005):** Systematic transperineal ultrasound-guided template biopsy of the prostate: Three-year experience. *Urology* 65:735-739.
- Pinthus, J.H. ; Witkos, M. ; Fleshner, N.E. ; Sweet, J. ; Evans, A. ; Jewett, M.A. ; Krahm, M. ; Alibhai, S. and Trachtenberg, J. (2006):** Prostate cancers scored as Gleason 6 on prostate biopsy are frequently Gleason 7 tumors at radical prostatectomy: implication on outcome. *J Urol* 176:979–984
- Polascik, T.J.; Oesterling J.E. and Partin, A.W. (1999):** Prostate specific antigen: A decade of discovery—What we have learned and where we are going. *J Urol* 162:293-306.
- Pondman, K. M.; Futterer, J. J.; Haken, B.; Kool, L. J. S.; Witjes, J.; Hambroek, T.; Macura, K. J. and Barentsz, J.O.(2008):** MR-Guided Biopsy of the Prostate: An Overview of Techniques and a Systematic Review *European urology* 54:517–527.
- Poulos, C.K. ; Daggy, J.K. and Cheng, L.(2005):** Preoperative prediction of Gleason grade in radical prostatectomy specimens: the influence of different Gleason grades from multiple positive biopsy sites. *Modern Pathology*18, 228–234
- Pound, C.R. ; Partin, A.W. and Epstein, J.I. (1997):** Prostate-specific antigen after anatomic radical retropubic prostatectomy. Patterns of recurrence and cancer control. *Clin North Am* 24:395.
- Presti, J.C. Jr. ; Chang, J.J. ; Bhargava, V. and Shinohara, K. (2000):** The optimal systematic prostate biopsy scheme should include 8 rather than 6 biopsies: results of a prospective clinical trial. *J Urol* 163:163–167.

- Prestigiacomo, A.F. and Stamey, T.A. (1996):** Physiological variation of serum prostate specific antigen in the 4.0 to 10.0 ng/ml range in male volunteers. *J Urol* 155:1977-1980.
- Rabbani F.(2007):** Editorial comment on: prostate cancer distribution in patients diagnosed by transperineal template-guided saturation biopsy. *Eur Urol* 52:723–724.
- Raboy, A.; Ferzli, G. and Albert, P. (1997):** Initial experience with extraperitoneal endoscopic radical retropubic prostatectomy. *Urology* 50:849–853
- Rajinikanth, A.; Manorharan, M.; Soloway, C.T.; Civantos, F.J. and Soloway, M.S. (2008):** Trends in Gleason Score: Concordance between biopsy and prostatectomy over 15 years. *Urology*.Elsaliver.
- Ramey,J.R.; Halpern,E.J. and Gomella,L.G.(2007):** Ultrasonography and Biopsy of the Prostate. Walsh, P.C; Retik, A.B.; Vaughan, Jr. E.D and Wein, A.J., Campbell's Urology, Vol. 3, (ed) 9th, Philadelphia, W.B. Saunders Co. PP.
- Rassweiler, J.; Frede, T.; Seemann,O.; Stock, C. and Sentker, L. (2001):** Telesurgical laparoscopic radical prostatectomy. Initial experience. *Eur Urol* 40:75–83.
- Rassweiler, J. ; Marrero, R. ; Hammady, A. ; Erdogru, T. ; Teber, D. and Frede, T. (2004):** Transperitoneal laparoscopic radical prostatectomy: ascending technique. *J Endourol* 18:593–599.
- Remzi, M.; Fong. Y.K.; Dobrovits, M. ;Anagnostou, T. Seitz, C.; Waldert, M.; Harik, M.;Marihart, S.; Marberger, M.and Djavan, B. (2005):** The Vienna nomogram: validation of a novel biopsy strategy defining the optimal number of cores based on patient age and total prostate volume. *J Urol* 174:1256 -1261.
- Riehmman, M. ; Rhodes, P.R. and Cook, T.D. (1993) :** Analysis of variation in prostate-specific antigen values. *Urology* 42:390-397.

- Robutti, F. ; Pilato, F.P. and Betta, P-G. (1989):** A new method of grading malignancy of prostate carcinoma using quantitative microscopic nuclear features. *Pathol Res Pract* 185:701-703.
- Roehl, K.A. ; Han, M. ; Ramos, C.G. ; Antenor, J.A. and Catalona, W.J. (2004):** Cancer progression and survival rates following anatomical radical retropubic prostatectomy in 3,478 consecutive patients: long-term results. *J Urol* 172:910–914.
- Rommel, F.M. ; Agusta, V.E. and Breslin, J.A. (1994):** The use of prostate specific antigen and prostate specific antigen density in the diagnosis of prostate cancer in a community based urology practice. *J Urol* 151:88-93.
- Roscigno, M.; Scattoni, V. and Bertini R.(2004):**Diagnosis of prostate cancer. *State of the art. Minerva Urol Nefrol* 56:123.
- Roumeguere, T. ; Bollens, R. ; Quackels, T. ; Bossche, M.V. ; Zlotta, A.R. and Schulman, C.C. (2003):** Radical prostatectomy: a prospective comparison of oncological and functional results between open and laparoscopic approaches. *World J Urol* 20:360–366.
- Rubin, M.A: Dunn, R.; Kambham, N.; Misick, C.P. and O'Toole, K.M. (2000)** Should a Gleason grade be assigned to a minute focus of carcinoma on needle biopsy. *Am J Surg Pathol.* 24:1634-40.
- Ruiz-Deya, G. ; Davis, R. ; Srivastav, S.K. ; M Wise, A. and Thomas, R. (2001):** Outpatient radical prostatectomy: impact of standard perineal approach on patient outcome. *J Urol* 166:581–586
- San Francisco, I.F. ; Dewolf, W.C. ; Rosen,S. ; Upton, M. and Olumi,A. F. (2003):**Extended prostate needle biopsy improves concordance of Gleason grading between prostate needle biopsy and radical prostatectomy. *The journal of urology* , vol.169, 136-168.
- Sakr, N. ; Pernick, C. and Butler, H. (2000):** The prevalence of high-grade, clinically occult prostatic adenocarcinoma and its relationship to high-grade prostatic intraepithelial neoplasia. *Mod Pathol* 13:113A.

- Salomon, L. ; Levrel, O. ; de la Taille, A. ; Anastasiadis, A.G. ; Saint, F. ; Zaki, S. ; Vordos, D. ; Cicco, A. ; Olsson, L.E. ; Hoznek, A. ; Chopin, D. ; and Abbou, C.C. (2002):** Radical prostatectomy by the retropubic, perineal and laparoscopic approach: 12 years of experience in one center. *Eur Urol* 42:104–110
- Scales, C.D. Jr. ; Jones, P.J. ; Eisenstein, E.L. ; Preminger, G.M. and Albala, D.M. (2005)** Local cost structures and the economics of robot assisted radical prostatectomy. *J Urol* 174:2323–2329.
- Schroeder, F.H. ; Blom, J.H. and Hop, W.C.(1985):** Grading of prostatic cancer (1): An analysis of the prognostic significance of single characteristics. *Prostate* 6:81-100.
- Schroder FH(2003):** Screening for prostate cancer. *Urol Clin North Am* 30:239.
- Seaman, E.; Whang, M. and Olsson, C.A. (1993) :** PSA density (PSAD). Role in patient evaluation and management. *Urol Clin North Am* 20:653-663.
- Sedelaar, J.P. ; Vijverberg, P.L. ; De Reijke, T.M. ; de la Rosette, J.J. ; Kil, P.J. ; Braeckman, J.G. and Hendrikx, A.J. (2001):** Transrectal ultrasound in the diagnosis of prostate cancer: state of the art and perspectives. *Eur Urol* 40:275–284.
- Sengupta, S.; Slezak, J.M. and Blute, M.L. (2006):** Trends in distribution and prognostic significance of Gleason grades on radical retropubic prostatectomy specimens between 1989 and 2001. *Cancer* 106: 2630-2635.
- Shannon, B.A.; McNeal, J.E. and Cohen, R.J. (2003):** Transition zone carcinoma of the prostate gland: a common indolent tumour type that occasionally manifests aggressive behaviour. *Pathology* 35:467–471.
- Singh, H. ; Canto, E.I. ; Shariat, S.F. ; Kadmon, D. ; Miles, B.J. ; Wheeler, T.M. and Slawin, K.M. (2004):** Improved detection of clinically significant, curable prostate cancer with systematic 12-core biopsy. *J Urol* 171:1089–1092

- Smith, D.S. and Catalona, W.J.(1994):** Rate of change in serum prostate specific antigen levels as a method for prostate cancer detection. *J Urol* 152:1163-1167.
- Sokoll, L.J. ; Mangold, L.A. and Partin, A.W. (2002):** Complexed prostate-specific antigen as a staging tool for prostate cancer: A prospective study in 420 men. *Urology* 60(4 Suppl 1):18-23.
- Sokoll, L.J. ; Chan, D.W. and Mikolajczyk, S.D. (2003):** Proenzyme PSA for the early detection of prostate cancer in the 2.5-4.0 ng/ml total PSA range: Preliminary analysis. *Urology* 61:274-276.
- Srigley, J.R. ; Amin, M.B. and Bostwick, D.G.(2000):** Updated protocol for the examination of specimens from patients with carcinomas of the prostate gland *Arch Pathol Lab Med* 124:1034-1039.
- Stamey, T.A. (1995):** Making the most out of six systematic sextant biopsies. *Urology* 45:2–12
- Stamey, T.A. ; Caldwell, M. ; McNeal, J.E. ; Nolley, R. ; Hemenez, M. and Downs, J. (2004):** The prostate specific antigen era in the United States is over for prostate cancer: what happened in the last 20 years? *J Urol* 172:1297–1301.
- Steinberg, D.M.; Sauvageot, J.; and Piantadosi, S. (1997):** Correlation of prostate needle biopsy and radical prostatectomy Gleason grade in academic and community settings. *Am J Surg Pathol* 21:566-576.
- Stenman, U.H.; Leinonen, J. and Alfthan, H.(1991):** A complex between prostate-specific antigen and alpha 1-antichymotrypsin is the major form of prostate-specific antigen in serum of patients with prostatic cancer: Assay of the complex improves clinical sensitivity for cancer. *Cancer Res* 51:222-226
- Stenman, U.H.; Hakama, M. and Knekt, P. (1994):** Serum concentrations of prostate specific antigen and its complex with alpha 1-antichymotrypsin before diagnosis of prostate cancer. *Lancet* 344:1594-1598

- Stephenson, R.A. and Stanford, J.L. (1997):** Population-based prostate cancer trends in the United States: Patterns of **change** in the era of prostate-specific antigen. *World J Urol* 15:331-335.
- Stephan, C.; Cammann, H. and Semjonow, A.(2002):** Multicenter evaluation of an artificial neural network to increase the prostate cancer detection rate and reduce unnecessary biopsies. *Clin Chem* 48:1279-1287.
- Stolzenburg, J.U. ; Rabenalt, R.; Do, M. ; Ho, K. ; Dorschner, W. ; Waldkirch, E. ; Jonas, U. ; Schutz, A. ; Horn, L. and Truss, M.C. (2005):** Endoscopic extraperitoneal radical prostatectomy: oncological and functional results after 700 procedures. *J Urol* 174:1271–1275.
- Susil, R.C.; Menard, C. and Krieger, A.(2006):** Transrectal prostate biopsy and fiducial marker placement in a standard 1.5 T magnetic resonance imaging scanner. *J Urol* 175:113–120.
- Sved, P.D.; Gomez, P. and Manoharan, M. (2004):** Limitations of biopsy Gleason grade implications for counseling patients with biopsy Gleason Score prostate cancer. *J. Urol.* 172: 98-102.
- Taneja, S.S. ; Hsu, E.I. and Cheli, C.D. (2002):** Complexed prostate-specific antigen as a staging tool: Results based on a multicenter prospective evaluation of complexed prostate-specific antigen in cancer diagnosis. *Urology* 60(4 Suppl 1):10-17.
- Takayama, T.K. ; Fujikawa, K. And Davie, E.W.(1997):** Characterization of the precursor of prostate-specific antigen. activation by trypsin and by human glandular kallikrein. *J Biol Chem* 272:21582-21588.
- Tavangar,S.M.; Razi, A. and Mashayekhi,R.(2004):** Correlation between prostate needle biopsy and radical prostatectomy Gleason gradings of 111 cases with prostatic adenocarcinoma. *Urol J.* Fall 1(4):246-9.
- Teichman, J.M.; Reddy, P.K. and Hulbert, J.C. (1995):** Laparoscopic pelvic lymph node dissection, laparoscopically assisted seminal vesicle mobilization, and total perineal prostatectomy versus radical retropubic prostatectomy for prostate cancer. *Urology* 45:823–830

- Tenke, P., Horti, J., Balint, P. and Kovacs B. (2007):** Prostate Cancer Screening. Ramon, J. and Denis, L. J., Prostate Cancer, Recent Results in Cancer Research, *Springer-Verla Berlin Heidelberg* PP. 65-82.
- Tewari ,P.C. and Bluestein(1996) :** Multiple forms of prostate specific antigen and the influences of immunoassay design on their measurement in patient serum. *J Clin Ligand Assay* 18:186-196.
- Thompson, I.M. ; Pauler, D.K. and Goodman, P.J.(2004):** Prevalence of prostate cancer among men with a prostate-specific antigen level $> \text{ or } = 4.0$ ng per milliliter. *N Engl J Med* 350:2239-2246.
- Tooher, R.; Swindle, P.; Woo, H.; Miller, J. and Maddern, G. (2006):**
Laparoscopic radical prostatectomy for localized prostate cancer: A systematic review of comparative studies. *J. Urology* 175: 2011-2017.
- Unal, D. ; Sedelaar, J.P. ; Aarnink, R.G. ; van Leenders, G.J. ; Wijkstra ,H. ; Debruyne, F.M. and de la Rosette, J.J. (2000):** Three-dimensional contrast-enhanced power Doppler ultrasonography and conventional examination methods: the value of diagnostic predictors of prostate cancer. *BJU Int* 86:58–64.
- Uzzo, R.G. ; Wei, J.T. and Waldbaum, R.S. (1995):** The influence of prostate size on cancer detection. *Urology* 46:831-836.
- Van Poppel, H. ; Goethuys, H. ; Callewaert, P. ; Vanuytsel, L. ; Van de Voorde, W.M. and Baert, L. (2000):** Radical prostatectomy can provide a cure for well-selected clinical stage T3 prostate cancer. *Eur Urol* 38:372–379.
- Van Poppel, H. ; Goethuys, H. ; De Ridder, D. ; Verleyen, P. ; Ackaert, K. ; Werbrouck, P. ; De Coster, M. and Baert, L. , the Members of the BUOS (2001):** Neoadjuvant therapy before radical prostatectomy: impact on progression free survival. *Uro-Oncology* 1:301–307
- Veltri, R.W. and Miller, M.C.(1999):** Free/total PSA ratio improves differentiation of benign and malignant disease of the prostate: Critical analysis of two different test populations. *Urology* 53:736-745.

- Vessella, R.L. ; Lange, P.H. and Partin, A.W.(2000):** Probability of prostate cancer detection based on results of a multicenter study using the AxSYM free PSA and total PSA assays. *Urology* 55:909-914.
- Vis, A.N. ; Boerma, M.O. and Ciatto, S. (2000):** Detection of prostate cancer: A comparative study of the diagnostic efficacy of sextant transrectal versus sextant transperineal biopsy. *Urology* 56:617-621.
- Wallace, D. ; Chisolm, G. and Hendry, W. (1975):** TNM classification for urological tumors (UICC)-1974. *Br J Urol* ; 47:1.
- Walsh, P.C. ; Lepor, H. and Eggleston, J.C. (1983):** Radical prostatectomy with preservation of sexual function: anatomical and pathological considerations. *Prostate* 4:473–485.
- Walsh, P.C. and Marschke, P.L. (2002):** Intussusception of the reconstructed bladder neck leads to earlier continence after radical prostatectomy. *Urology* 59:934–938.
- Weldon, V.E. and Tavel, F.R. (1988):** Potency-sparing radical perineal prostatectomy: anatomy, surgical technique and initial results. *J Urol* 140:559–562
- Weldon, V.E. ; Tavel, F.R. ; Neuwirth, H. and Cohen, R. (1995):** Failure of focal prostate cancer on biopsy to predict focal prostate cancer: the importance of prevalence. *J Urol* 154:1074–1077
- Weldon, V.E. (2002):** Technique of modern radical perineal prostatectomy. *Urology* 60:689–694
- Whitmore, Jr. W.F.(1956):** Hormone therapy in prostatic cancer. *Am J Med* 21:697.
- Woodrum, D.L. ; Brawer, M.K. and Partin, A.W.(1998):** Interpretation of free prostate specific antigen clinical research studies for the detection of prostate cancer. *J Urol* 159:5-12.

- Young, R.H. ; Srigley, J.R. and Amin, M.B. (2000):** Tumors of the prostate gland, seminal vesicles, male urethra, and penis. *In: Atlas of Tumor Pathology, 3rd series, fascicle 28.* Washington, DC: American Registry of Pathology.
- Zangos, S.; Eichler, K. and Engelmann, K.(2005):** MR-guided transgluteal biopsies with an open low-field system in patients with clinically suspected prostate cancer: technique and preliminary results. *Eur Radiol 15:174–182.*
- Zangos, S.; Herzog, C. and Eichler, K.(2007):** MR-compatible assistance system for punction in a high-field system: device and feasibility of transgluteal biopsies of the prostate gland. *Eur Radiol 17:1118–1124.*
- Zeng, J. ; Bauer, J. ; Zhang, W. ; Sesterhenn, I. ; Moul, J. and Mun, S.K. (1999):** Prostate biopsy schemes: 3-D visualization- based evaluation. *Stud Health Technol Inform 62:390–391.*
- Zincke, H. ; Oesterling, J.E. ; Blute, M.L. ; Bergstralh, E.J. ; Myers, R.P. and Barrett, D.M. (1994):** Long-term (15 years) results after radical prostatectomy for clinically localized (stage T2c or lower) prostate cancer. *J Urol 152:1850–1857.*